Online inquiry

IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11568MR)

This product GTTS-WQ11568MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD276 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001024736.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 80381
UniProt ID Q5ZPR3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 0, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ11568MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8030MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ9896MR IVTScrip™ mRNA-Anti-pcrV, KB001-A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA KB001-A
GTTS-WQ2072MR IVTScrip™ mRNA-Anti-Canlupfam PDCD1, AH-PD1(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AH-PD1
GTTS-WQ4584MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-986004
GTTS-WQ9639MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ1852MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA AG1-25
GTTS-WQ8579MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ12728MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, OMP-305B83(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA OMP-305B83
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW